EP3470077A1 — Method to predict response to pharmacological chaperone treatment of diseases
Assigned to Amicus Therapeutics Inc · Expires 2019-04-17 · 7y expired
What this patent protects
A method of compiling a treatment reference table that indicates the responsiveness of one or more specific mutations of ±-Gal A to a specific pharmacological chaperone, the method comprising: analysing in vitro the response to the specific pharmacological chaperone in a host c…
USPTO Abstract
A method of compiling a treatment reference table that indicates the responsiveness of one or more specific mutations of ±-Gal A to a specific pharmacological chaperone, the method comprising: analysing in vitro the response to the specific pharmacological chaperone in a host cell that has been transformed with a nucleic acid vector that encodes a first mutant ±-Gal A and compiling a table listing responsive and non-responsive mutant forms of ±-Gal A. The specific pharmacological chaperone is 1-deoxygalactonojirimycin or a pharmaceutically salt or ester and the first cell is HEK-293 MSR cell.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.